Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06391177
Other study ID # VONO-401
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date June 3, 2024
Est. completion date August 2024

Study information

Verified date June 2024
Source Phathom Pharmaceuticals, Inc.
Contact Phathom Medical Information
Phone 1-888-775-7248
Email medicalinformation@phathompharma.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective is to determine the pharmacokinetics (PK) of vonoprazan in breast milk of healthy lactating women who have received vonoprazan administered once daily for 4 consecutive days.


Recruitment information / eligibility

Status Recruiting
Enrollment 8
Est. completion date August 2024
Est. primary completion date August 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. The participant is a healthy lactating woman at least 18 years of age at the time of signing the informed consent form (ICF). 2. The participant has delivered a normal term infant (at least 37 weeks gestation) and has been breastfeeding or actively pumping breast milk for at least 4 weeks postpartum prior to the first dose. 3. The participant is willing to not breastfeed or otherwise use her breast milk during administration of vonoprazan and until at least 5 days after the last dose of the study drug. 4. The participant has confirmed that her breastfed infant is able to feed from a bottle. 5. The participant agrees to collect all breast milk from pre-dose to 24 hours after the last dose administration, using an electric pump. 6. The participant is considered by the investigator to be in good general health as determined by medical history, clinical laboratory test results, vital sign measurements, 12-lead ECG results, and physical examination findings at Screening. 7. Participants of childbearing potential must use an acceptable method of birth control (ie, diaphragm with spermicide, intrauterine device, condom with foam or vaginal spermicide, oral contraceptives, or abstinence) or be surgically sterile (ie, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy). All participants must have a negative pregnancy test at Screening and before the first dose of study drug (Baseline). 8. The participant agrees to comply with all protocol requirements. 9. The participant is able to provide written informed consent. Exclusion Criteria: 1. The participant has a positive pregnancy test at Screening or Baseline, is planning to become pregnant before, during, or within 4 weeks after participating in this study, or intends to donate ova during this time period, or is of childbearing potential and not using an effective contraceptive method. 2. The participant has a history of breast implants, breast augmentation, or breast reduction surgery that significantly impacts breastfeeding or collection of milk from one or both breasts. 3. The participant has signs or symptoms of mastitis or other condition that would prevent the collection of milk from one or both breasts. 4. The participant has undergone prior esophageal and/or gastrointestinal surgeries that may affect study drug absorption. 5. The participant has undergone surgery (other than cesarean section) within 30 days before the first dose of study drug. 6. The participant has a positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus types 1 or 2 antibodies at Screening. 7. The participant has any other clinically significant findings on physical examination, clinical laboratory abnormalities, or ECG results that preclude participation in the study, as deemed by the investigator. 8. The participant has used any prescription (excluding hormonal birth control) and/or over-the-counter medications (including cytochrome P450 3A4 inducers), including herbal or nutritional supplements, within 14 days before the first dose of study drug, and/or is expected to require any such medication during the course of the study until end of the Treatment Period. Use of multivitamins and acetaminophen (up to 2 g per day) is permissible. 9. The participant has consumed grapefruit and/or grapefruit juice, Seville orange, or Seville orange-containing products (eg, marmalade) within 7 days before the first dose of study drug and/or is expected to be unable to abstain through the study. 10. The participant is a smoker or has used nicotine or nicotine-containing products (eg, snuff, nicotine patch, nicotine chewing gum, mock cigarettes, or inhalers) within 6 months before the first dose of study drug. 11. The participant has a history of alcohol abuse or drug dependency within 12 months before the first dose of study drug. 12. The participant has a positive test result for drugs of abuse, alcohol, or cotinine (indicating active current smoking) at Screening, Baseline, or Day 4 (Check-in). 13. The participant is involved in strenuous activity or contact sports within 24 hours before the first dose of study drug and during the study. 14. The participant has a history of relevant drug and/or food allergies (ie, any significant food allergy that could preclude a standard diet in the clinical research unit). 15. The participant has received study drug in another investigational study (including vonoprazan) within 30 days prior to start of the Screening Period. 16. The participant has a history of hypersensitivity or allergies to vonoprazan or any of its formulation excipients (D-mannitol, microcrystalline cellulose, hydroxypropyl cellulose, fumaric acid, ascorbic acid, croscarmellose sodium, magnesium stearate, hypromellose, polyethylene glycol 8000, titanium dioxide, or ferric oxide red). 17. In the opinion of the investigator, the participant is not suitable for entry into the study.

Study Design


Intervention

Drug:
Vonoprazan
Oral tablet.

Locations

Country Name City State
United States PPD Development, LP Las Vegas Nevada

Sponsors (1)

Lead Sponsor Collaborator
Phathom Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Area Under the Drug Concentration-time Curve from Time 0 to 24 Hours (AUC0-24) Following the Last Dose of Vonoprazan in Breast Milk From dosing on Day 4 through 24 hours postdose
Primary Maximum Drug Concentration (Cmax) of Vonoprazan in Breast Milk From dosing on Day 4 through 24 hours postdose
Primary Minimum Drug Concentration (Cmin) of Vonoprazan in Breast Milk From dosing on Day 4 through 24 hours postdose
Primary Average Drug Concentration (Cavg) of Vonoprazan in Breast Milk From dosing on Day 4 through 24 hours postdose
Secondary Total Amount of Vonoprazan Excreted in Breast Milk From dosing on Day 4 through 24 hours postdose
Secondary Percentage of Vonoprazan Excreted in Breast Milk Relative to Dose From dosing on Day 4 through 24 hours postdose
Secondary Estimated Infant Daily Dose of Vonoprazan From dosing on Day 4 through 24 hours postdose
Secondary Percentage Relative Infant Dose to the Maternal Dose of Vonoprazan From dosing on Day 4 through 24 hours postdose
See also
  Status Clinical Trial Phase
Recruiting NCT05061732 - Helicobacter Pylori Eradication and Follow-up Phase 4
Completed NCT03779074 - Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies Phase 3
Completed NCT06076681 - A Study to Evaluate Preliminary Helicobacter Pylori Eradication After Multiple Doses of TNP-2198 Capsules Combined With Rabeprazole Sodium Enteric-coated Tablets, or Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules Phase 1/Phase 2
Recruiting NCT05329636 - Auto Fecal Microbial Transplant Post Helicobacter Pylori Antibiotic Therapy Phase 1/Phase 2
Recruiting NCT05065138 - Comparison of Helicobacter Pylori Eradication Effect Before and After Training of Gastroenterologists N/A
Completed NCT05049902 - Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication Phase 4
Not yet recruiting NCT06200779 - Tailored vs. Empirical Helicobacter Pylori Infection Treatment Phase 4
Not yet recruiting NCT06037122 - Efficacy of Low-dose Vonoprazan for Helicobacter Pylori Eradication
Completed NCT04617613 - Comparing Different Regimens for Eradication of Helicobacter Pylori in Kuwait Phase 4
Completed NCT02873247 - Standardize Communication With General Practitioner & Patient for Improved Eradication of Helicobacter Pylori
Withdrawn NCT02552641 - Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole Phase 4
Completed NCT02557932 - Comparison of 7-day PPI-based Standard Triple Therapy and 10-day Bismuth Quadruple Therapy for H. Pylori Eradication Phase 3
Recruiting NCT02249546 - Efficacy of Acetylcysteine-containing Triple Therapy in the First Line of Helicobacter Pylori Infection Phase 4
Completed NCT01933659 - Anti-H. Pylori Effect of Deep See Water Phase 3
Unknown status NCT01464060 - 14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication Phase 4
Completed NCT00841490 - Oral H. Pylori Prevalence in Intellectually & Developmentally Disabled Adults N/A
Recruiting NCT05549115 - Susceptibility-Guided Sequential Therapy for Helicobacter Pylori Infection N/A
Recruiting NCT05728424 - One vs Two Weeks Treatment for H.Pylori Eradication A RANDOMIZED NON-INFERIORITY PLACEBO CONTROLLED TRIAL Phase 3
Recruiting NCT05997433 - Efficacy of 7-day Versus 14-day Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori(SHARE2302) N/A
Completed NCT04708405 - The Relationship Between Helicobacter Pylori Infection and Inflammatory Bowel Diseases: A Real-life Observation